ADDED
As of March 9, 2026, the registrant had 7,299,687 shares of common stock outstanding.
We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances , except as otherwise required by law.
We are a biopharmaceutical company focused on leveraging our proprietary technology platform to develop innovative products with effective oral delivery of previously difficult to deliver molecules.
The license agreement is for the development and commercialization of our product, TLANDO, an oral treatment indicated for testosterone replacement therapy ( testosterone replacement therapy or TRT ) in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism) comprised of testosterone undecanoate ( testosterone undecanoate or TU ) and any post-marketing studies required by the United States Food and Drug Administration ( FDA ) will also be the responsibility of Verity.
In April 2025, we entered into a License and Supply Agreement (the Ach License Agreement ) with Ach , pursuant to which we granted to Ach an exclusive license to commercialize TLANDO with respect to the field, specific to Brazil (the Ach Territory ).
Under the agreement, we are entitled to receive fees upon the achievement of certain regulatory milestones, royalties on net sales and will supply TLANDO to Ach at an agreed transfer price.
We retain development and commercialization rights for TLANDO outside of the United States, Canada, South Korea, the GCC and Brazil.
Additional clinical development pipeline candidates include: LPCN 1154 for postpartum depression ( PPD ); LPCN 2201 for major depressive disorder ( MDD ); LPCN 2203 for essential tremor; LPCN 2101 for epilepsy; and LPCN 2401 for improved body composition in obesity management.
We are currently exploring partnerships for our liver program LPCN 1148 for the management of decompensated cirrhosis including prevention of the recurrence of overt hepatic encephalopathy ( overt hepatic encephalopathy or OHE ); LPCN 2401 for improved body composition as adjunct therapy to incretin mimetics use in obesity management; and LPCN 1107, our candidate for prevention of pre-term birth.
Our Pipeline Product Candidates Our pipeline of clinical development candidates includes LPCN 1154 for PPD, LPCN 2201 for MDD, LPCN 2101 for epilepsy, and LPCN 2203 for essential tremor.
REMOVED
As of March 11, 2025, the registrant had 5,350,356 shares of common stock outstanding.
We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law .
We are a biopharmaceutical company focused on leveraging our proprietary Lip ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules.
We entered into a license agreement for the development and commercialization of our product candidate, TLANDO , an oral treatment indicated for testosterone replacement therapy ( testosterone replacement therapy or TRT ) in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism) comprised of testosterone undecanoate ( testosterone undecanoate or TU ).
Any post-marketing studies required by the United States Food and Drug Administration ( FDA ) will also be the responsibility of our Licensee, Verity.
Additional clinical development pipeline candidates include: LPCN 1154 for postpartum depression ( PPD ); LPCN 2101 for epilepsy; LPCN 2203 for essential tremor and LPCN 2401 for improved body composition in obesity management.
We are currently exploring partnerships for our liver programs LPCN 1144, our candidate for treatment of MASH and LPCN 1148 for the management of cirrhosis including prevention of the recurrence of overt hepatic encephalopathy ( overt hepatic encephalopathy or OHE ); LPCN 2401 for improved body composition in obesity management as adjunct therapy as an adjunct therapy to or as a monotherapy post cessation of incretin mimetics use; and LPCN 1107, our candidate for prevention of pre-term birth.
Our Pipeline Product Candidates Our pipeline of clinical development candidates includes LPCN 1154 for PPD, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, and LPCN 2401 as an aid for improved body composition in obesity management.
5 Our products are based on our proprietary Lip ral drug delivery technology platform.
In addition, in September 2024, we granted SPC an exclusive, royalty-bearing license to commercialize TLANDO in South Korea and in October 2024 we granted Pharmalink an exclusive license to commercialize TLANDO in the GCC countries.